Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

¸»´Üºñ´ëÁõ ȯÀÚ¿¡¼­ ¼Ò¸¶Å佺Ÿƾ À¯»çü »ç¿ë¿¡ ´ëÇÑ ±Ç°í¾È Medical Treatment with Somatostatin Analogues in Acromegaly: Position Statement

´ëÇѳ»°úÇÐȸÁö 2019³â 94±Ç 6È£ p.485 ~ 494
Áø»ó¿í, ±¸Ã¶·æ, ±èº´ÁØ, ±è¼º¿î, ¹Ú°æÇý, ¼Û±âÈ£, ¿À½ÂÁØ, À±Çö±¸, ÀÌÀºÁ÷, ÀÌÁ¤¹Î, ÀÓÁ¤¼ö, ±èÁ¤Èñ, ±è±¤ÁØ, ÁøÈï¿ë, ±è´ëÁß, ÀÌ°æ¾Ö, ¹®¼º¼ö, ÀÓµ¿ÁØ, ½Åµ¿¿±, ±è¼¼È­, ±Ç¹ÎÁ¤, ±èÇÏ¿µ, ±èÁøÈ­, ±èµ¿¼±, ±èÁ¾È­,
¼Ò¼Ó »ó¼¼Á¤º¸
Áø»ó¿í ( Chin Sang-Ouk ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ´ë»ç³»°ú

±¸Ã¶·æ ( Ku Cheol-Ryong ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø ³»ºÐºñ³»°ú
±èº´ÁØ ( Kim Byung-Joon ) 
°¡Ãµ´ëÇб³ ±æº´¿ø ³»°ú
±è¼º¿î ( Kim Sung-Woon ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ´ë»ç³»°ú
¹Ú°æÇý ( Park Kyeong-Hye ) 
±¹¹Î°Ç°­º¸Çè°ø´Ü Àϻ꺴¿ø ³»°ú
¼Û±âÈ£ ( Song Kee-Ho ) 
°Ç±¹´ëÇб³ ÀÇ°ú´ëÇÐ °Ç±¹´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú
¿À½ÂÁØ ( Oh Seung-Joon ) 
°æÈñ´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ´ë»ç³»°ú
À±Çö±¸ ( Yoon Hyun-Koo ) 
´Ü±¹´ëÇб³ ÀÇ°ú´ëÇÐ Á¦ÀÏ¿©¼ºº´¿ø ³»ºÐºñ³»°ú
ÀÌÀºÁ÷ ( Lee Eun-Jig ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø ³»ºÐºñ³»°ú
ÀÌÁ¤¹Î ( Lee Jung-Min ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
ÀÓÁ¤¼ö ( Lim Jung-Soo ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¿øÁÖ¼¼ºê¶õ½º±âµ¶º´¿ø ³»ºÐºñ´ë»ç³»°ú
±èÁ¤Èñ ( Kim Jung-Hee ) 
¼­¿ï´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú
±è±¤ÁØ ( Kim Kwang-Joon ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç ³ë³â³»°ú
ÁøÈï¿ë ( Jin Heung-Yong ) 
ÀüºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±è´ëÁß ( Kim Dae-Joong ) 
¾ÆÁÖ´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú
ÀÌ°æ¾Ö ( Lee Kyung-Ae ) 
ÀüºÏ´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
¹®¼º¼ö ( Moon Seong-Su ) 
µ¿±¹´ëÇб³ ÀÇ°ú´ëÇÐ °æÁÖº´¿ø ³»ºÐºñ³»°ú
ÀÓµ¿ÁØ ( Lim Dong-Jun ) 
°¡Å縯´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
½Åµ¿¿± ( Shin Dong-Yeop ) 
¿¬¼¼´ëÇб³ ÀÇ°ú´ëÇÐ ¼¼ºê¶õ½ºº´¿ø ³»ºÐºñ³»°ú
±è¼¼È­ ( Kim Se-Hwa ) 
°¡Å縯°üµ¿´ëÇб³ ÀÇ°ú´ëÇÐ ³»°úÇб³½Ç
±Ç¹ÎÁ¤ ( Kwon Min-Jeong ) 
ÀÎÁ¦´ëÇб³ ÀÇ°ú´ëÇÐ ºÎ»ê¹éº´¿ø ³»ºÐºñ´ë»ç³»°ú
±èÇÏ¿µ ( Kim Ha-Young ) 
¿ø±¤´ëÇб³ »êº»º´¿ø ³»ºÐºñ³»°úÇб³½Ç
±èÁøÈ­ ( Kim Jin-Hwa ) 
Á¶¼±´ëÇб³º´¿ø ³»ºÐºñ´ë»ç³»°ú
±èµ¿¼± ( Kim Dong-Sun ) 
ÇѾç´ëÇб³ ÀÇ°ú´ëÇÐ ³»ºÐºñ´ë»ç³»°úÇб³½Ç
±èÁ¾È­ ( Kim Jong-Hwa ) 
¼¼Á¾º´¿ø ³»ºÐºñ´ë»ç³»°ú

Abstract


Acromegaly is a chronic disorder caused by excessive growth hormone (GH) secretion. In most cases, the excess GH originates from GH-producing pituitary adenomas. Surgery is the preferred first-line treatment for patients with acromegaly, but medical management is considered when the disease persists after surgery or in cases where patients refuse surgery or are poor candidates for surgery. Somatostatin analogues are commonly used to treat acromegaly. The Korean Endocrine Society and the Korean Neuroendocrine Study Group have developed a position statement for the use of somatostatin analogues in the medical treatment of acromegaly. This position statement is based on evidence from the current literature and expert opinions. In the case of discrepancies among expert opinions, the experts voted to determine the recommended approach.

Å°¿öµå

Acromegaly; Somatostatin; Octreotide; Lanreotide; Pasireotide

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

  

µîÀçÀú³Î Á¤º¸

KCI
KoreaMed
KAMS